Evalve, Mitralign Deals: Heart Valves Draw New Device Investors
Executive Summary
Over the last few years, interventional heart valve technologies have been among the most popular segments of the cardiovascular device market with venture investors. This popularity has resulted in some VCs concluding that the space has become saturated. While the market may be getting tougher to enter for newcomers, the successful financing rounds recently closed by Evalve and Mitralign show that investors--including new device investors--remain bullish on companies that can demonstrate an effective percutaneous alternative to existing surgical procedures.
You may also be interested in...
Proving Device Incubation Works: An Interview with The Foundry
A decade ago, incuabators were seen as the best medicine for what then ailed the medical device industry, most notably a complex regulatory pathway and a difficult venture financing climate. Perhaps not surprisingly, as both the regulatory path and venture financing grew easier in the mid 2000s, incubators began to struggle, victims of their own financing problems. More recently, two huge acquisitions, Abbott's purchase of Evalve and Medtronic's of Ardian, suggest that at least one incubator, The Foundry, is proving that incubation works.
Abbott Moves into Heart Valves with Evalve Deal
The hottest major interventional cardiology company, Abbott, moves into the hottest interventional clinical space, catheter-based heart valve therapy, with the acquisition of Evalve, providing Abbott with a platform to build a structural heart disease device business.
Abbott Moves into Heart Valves with Evalve Deal
The hottest major interventional cardiology company, Abbott, moves into the hottest interventional clinical space, catheter-based heart valve therapy, with the acquisition of Evalve, providing Abbott with a platform to build a structural heart disease device business.